A Potential Role of Vitamin D on Platelet Leukocyte Aggregation and Pathological Events in Sepsis: An Updated Review

Azzah Alharbi
Medical Microbiology and Parasitology Department, King Abdulaziz University, Jeddah, Saudi Arabia

Abstract: Vitamin D deficiency and sepsis are both significant global health problems. Insufficient vitamin D is considered to be a pathogenically relevant factor of sepsis-related deaths; however, a causal relationship has not yet been demonstrated. Recently, vitamin D has been an exciting field of research owing to the identification of vitamin D receptors on many extra skeletal tissues and cells, suggesting an unexpected role on body physiology, beyond its effects on bone homeostasis. However, while the role of vitamin D on bone health is widely understood and has been successfully translated into clinical applications and public health policies, recent evidence supporting its role in other physiological and pathological processes has not been fully established. In sepsis, there is an induction of local intracellular vitamin D activity by most immune cells, including lymphocytes, macrophages, neutrophils, and dendritic cells, as well as vascular endothelial cells, to ensure efficient clearance of infective microorganisms and mediate anti-inflammatory and tolerogenic effects. The literature suggests an association between low vitamin D levels and sepsis, but clinical trials have yielded contradictory results. A greater understanding of this role may improve disease management. This article reviews the available knowledge regarding vitamin D in immune function, emerging literature regarding the association between its deficiency and sepsis, as well as presenting its potential effect on platelet leukocyte aggregations (PLAs), a significant pathology in sepsis. It also summarizes clinical trials involving vitamin D supplementation during critical illness and sepsis and addresses the impact of relevant factors of sepsis pathogenesis on the efficacy of vitamin D supplementation, which could contribute to the reported inconsistencies. Looking ahead, further studies are required to uncover the possible modulatory relationship between vitamin D and sepsis to define better cut-offs for its levels, proper timing of its administration, and the optimum dosage for best management.

Keywords: infection, inflammation, cellular interaction, 25(OH)D3 deficiency

Background
Vitamin D (VD), is a steroid hormone and a crucial nutrient that is reported to control a wide range of physiological processes. Several sources of VD are available in the form of D$_2$, known as ergocalciferol, and D$_3$, known as cholecalciferol. VD$_2$ is produced from ergosterol found mainly in fungi and also in some plants upon ultraviolet irradiation. Approximately 80% of VD$_3$ is synthesized endogenously in the human skin as 7-dehydrocholesterol in response to ultraviolet
ray exposure from sunlight, and about 20% is provided through diet. Inside the body, VD$_2$ and VD$_3$ undergo two consecutive steps of hydroxylation in the liver and then kidneys to be converted into their active compounds, 25(OH)D3 calcidiol (a clinical marker of plasma VD level), and 1,25(OH)2D3 calcitriol, respectively.

In addition to its well-known effects on calcium and phosphate metabolism to ensure bone health, VD has an emerging immune modulatory effect. VD is involved in immune system regulation; it regulates the action of suppressor T lymphocytes, the synthesis of cytokines, and acts by modulating the processes of cellular apoptosis. In the 19th century, prior to the development of effective antibiotics, VD was serendipitously used to cure infections, such as tuberculosis, through sunlight exposure and administration of cod liver oil, which are the main sources of VD. The Nobel Prize for medicine or physiology in 1903 was awarded to Finsen for his contribution in treating lupus vulgaris, a skin disease caused by *Mycobacterium tuberculosis* with ultraviolet (UV) light. Since then, some cross-sectional studies have suggested an inverse correlation between lower levels of VD and increased infections, such as tuberculosis (TB) and upper respiratory tract infections. In 1977, it was reported that children with malnutritional rickets were more prone to lung infections associated with an apparent radiographic pulmonary abnormalities called “rachitic lung.” However, little attention has been paid to these studies owing to the subsequent discovery and application of antibiotic therapy for infections.

Over the past three decades, Finsen’s work has received renewed attention as a consequence of multiple epidemiological studies showing a strong correlation between VD deficiency and the incidence of different infectious diseases, including pneumonia and sepsis. A significantly higher rate of such infections were reported during winter when exposure to sunlight, the major source of VD, is reduced. Since then, extensive studies of VD and incidence of infection have been published. Most of them focused on respiratory tract infections and consistently revealed the link between low VD plasma level (25(OH)D3) and the risk of acute respiratory infections. These findings were further confirmed by several randomized clinical trials (RCTs) that reported the protective effect of VD supplementation in reducing the risk of acute respiratory infections by 25% at doses of 400–1000 IU per day for 12 months, particularly in those with a baseline of <25 nmol/l.

During sepsis, there is growing evidence that VD deficiency is strongly associated with sepsis risk, pathogenesis, and outcomes as described later, but to date, these data could not be applied clinically. Several clinical trials aimed at analyzing the effects of supplementing VD on the outcomes of critical illness including sepsis have reported contradictory results as shown in Table 1.

Given the fact that sepsis is the most common cause of critical illness, all RCTs investigating the effect of VD supplementation for critically ill and septic adult patients controlled with a placebo were retrieved. The databases of Pumped, Scopus, Medline, Embase, Web of Science, and Clinical Trials.gov were used to search for the following words: RCT, administration, supplementation, vitamin D, vitamin D$_2$, vitamin D$_3$, cholecalciferol, ergocalciferol, calcitriol, calcidiol, 25-hydroxyvitamin D$_3$, 25(OH)D$_3$, 1,25-dihydroxyvitamin D$_3$, 1,25(OH)2D$_3$, sepsis, critical illness, intensive care unit, septic shock. All critical and septic cases with low VD plasma levels (25(OH)D3 ≤50 nmol/l) at admission were eligible for inclusion.

In some studies, the administration of VD resulted in significant increases in leukocyte mRNA expression of cathelicidin (LL-37, antimicrobial peptide) and plasma cathelicidin, significant reductions in IL-1β and 1L-6 among septic patients, and showed a reduction in 30-day ICU readmission in septic cases, a lower hospital death rate among critically ill patients with severe VD deficiency (25(OH)D3 ≤30 nmol/l), a significant decrease in the duration of hospital stay, a reduction in the duration of respiratory support with mechanical ventilators and hospitalization, and a reduction in mortality rate in the ICU among the critically ill. However, other studies demonstrated the ineffectiveness of VD supplementation on the mortality rate and duration of hospital stay.

VD deficiency and sepsis are very common, and both conditions frequently coexist clinically. However, neither the effects of its deficiency on the pathogenesis of the disease and outcomes nor the effects of the disease itself on the correct assessment of VD status have yet been estimated. Such effects may contribute to the confusion about positivity and negativity of VD effects in the reported results so far. For the first time, this paper discusses the role of VD in the pathogenesis of sepsis with particular focus on platelet leukocyte aggregations (PLAs) and how it may reduce aggregate formation as well as their adherence to the endothelium to mitigate sepsis progression. It also addresses the impact of relevant factors of...
# Table 1 Randomized Clinical Trial of Vitamin D Reinforcement in Critical Ill and Sepsis

| Study          | Participant’s Conditions | Number | Age                  | Intervention                                                                 | Changes in Vitamin D Level After Intervention | Changes in Markers of Immune Function | Clinical Outcomes                                                                 |
|----------------|--------------------------|--------|----------------------|-----------------------------------------------------------------------------|-----------------------------------------------|-------------------------------------|--------------------------------------------------------------------------------|
| Amrein et al, 2011 | Critical ill patients    | 36     | 12                   | Double-blind placebo and VD group Orally                                    | Not measured                                   | No significant effect in 28 mortality, Hospital stays and ICU stays.            |
|                |                          |        |                     | Both placebo and VD group 62±16 year                                        |                                               |                                     |
|                |                          |        |                     | Single dose of 540,000 IU Cholecalciferol or matched placebo Orally           |                                               |                                     |
|                |                          |        |                     | Placebo group 35.25 ± 9.25                                                  |                                               |                                     |
|                |                          |        |                     | VD group 32.75 ± 5                                                          |                                               |                                     |
|                |                          |        |                     | At 7th day                                                                   |                                               |                                     |
|                |                          |        |                     | Placebo group 34.25 ± 10.5                                                   |                                               |                                     |
|                |                          |        |                     | VD group 95.5 ± 41.25                                                        |                                               |                                     |
| Leaf et al, 2014 | Severe sepsis            | 31     | Placebo group 58     | Double-blind placebo and VD group 68 (54–70) year                           | Significant increase in 1,25-D concentration  | Significant increase in Leukocyte mRNA Expression of cathelicidin at 24 h of  |
|                |                          |        |                     | Placebo group 49–69 year                                                     | after 6 hours in VD group- versus placebo-    | Leukocyte mRNA Expression of cathelicidin at 24 h of calcitriol administration |
|                |                          |        |                     | VD group 68 (54–70) year                                                     | (75.7 [52.1–115.5] and 16.9 [9.0–26.9] pg/mL) | No difference between groups inTNF-α, IL-1, IL-2, IL-10, IL-6, And Cathelicidin (LL-37) |
| Amrein et al, 2014 | Critical ill patients    | 33     | Placebo group 38     | Double-blind placebo and VD group 238 (63.9) year                           | No significant effect in CRP                  | No significant effect in duration of hospital stays, hospital death rate 6-month deaths |
|                |                          |        |                     | Placebo group 238 (237)                                                     |                                               | Lower hospital death rate among subgroup of severe vitamin deficiency (25(OH)D3 ≤12 ng/mL) |
|                |                          |        |                     | Placebo group 88.75                                                         |                                               |                                     |
| Quraishi et al, 2015 | Sepsis                  | 32     | Placebo group 65     | Double-blind placebo and VD group 50 (58–70) year                           | Significant increase in cathelicidin LL-37 in VD group | 30-day ICU readmission rate is 20% in placebo group And 0% in both vitamin D group |
|                |                          |        |                     | Placebo group 64 (66–66)                                                     |                                               | No difference ICU length of stay.                                                |
|                |                          |        |                     | Placebo group 400,000 IU                                                    |                                               |                                     |
|                |                          |        |                     | Placebo group 62 (59–67)                                                     |                                               |                                     |
|                |                          |        |                     | Single dose of 200,000 IU or 400,000 IU of cholecalciferol or matched placebo |                                               |                                     |
|                |                          |        |                     | Oral                          |                                               |                                     |
|                |                          |        |                     | Placebo group 47.5 (32.5–55)                                                 |                                               |                                     |
|                |                          |        |                     | VD group 400,000 IU (37.5 (30–50))                                            |                                               |                                     |
|                |                          |        |                     | Placebo group 400,000 IU                                                     |                                               |                                     |
|                |                          |        |                     | VD group 400,000 IU (42.5 (32.5–62.5))                                       |                                               |                                     |
|                |                          |        |                     | At 5th day                                                                   |                                               |                                     |
|                |                          |        |                     | Placebo group 47.5 (27.5–57.5)                                                |                                               |                                     |
|                |                          |        |                     | VD group 200,000 IU (55 (40–62.5))                                            |                                               |                                     |
|                |                          |        |                     | VD group 400,000 IU (72.5 (80–102.5))                                         |                                               |                                     |

(Continued)
Table 1 (Continued).

| Study                  | Participant’s Conditions | Number | Age | Intervention | Changes in Vitamin D Level After Intervention | Changes in Markers of Immune Function | Clinical Outcomes |
|------------------------|--------------------------|--------|-----|--------------|-----------------------------------------------|--------------------------------------|-------------------|
| Han et al, 2016a        | Intensive care unit patients | Placebo group 10 VD group 50,000 IU (50,000 IU) 10 VD group 100,000 IU (100,000 IU) 11 | Placebo group 64.8 VD group 56.4 VD group 68.1 | Placebo group 10 VD group 50,000 IU (50,000 IU) 10 VD group 100,000 IU (100,000 IU) 11 | 25(OH)D3 (nmol/L) Baseline Placebo group 53.75 VD group 50,000 IU 58 VD group 100,000 IU 50 | No significant effect in antimicrobial peptide cathelicidin (LL-37) | Significant reduction in duration of hospital stay in both vitamin D group |
| National Heart and Network, 2019b | Critical ill | Placebo group 540 VD group 530 | Placebo group 56 ±15.9 VD group 54.6±16.7 | Placebo group 540 VD group 530 | 25(OH)D3 (nmol/L) Baseline Placebo group 27.5±11.75 VD group 28 ± 12 | Not measured | No significant effect in 28 day death rate, 90 day hospital death rate, duration of stay at hospital and other health care facility and duration respiratory support free time |
| Miri et al, 2019c       | Critical ill | Placebo group 18 VD group 22 | Placebo group 56 ± 22.1 VD group 52 ± 22.1 | Placebo group 18 VD group 22 | 25(OH)D3 (ng/dl) Baseline placebo group 28.38 ± 18.23 VD group 8.43 ± 6.8 | Not measured | Reduction in the duration of respiratory support with mechanical ventilators, the duration of hospitalization, and mortality rate in the ICU |

*Abbreviations: VD, vitamin D; ICU, intensive care unit; TNF, tumor necrosis factor; CRP, C reactive protein; hsCRP, high sensitivity C reactive protein.*
sepsis pathogenesis on the effectiveness of VD supplementation, which could contribute to clarification of the controversy in the reported results.

**Association Between Vitamin D Deficiency and Sepsis**

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to an infection.\(^{38}\) It is a fast-growing international health issue that imposes a substantial economic burden. Worldwide, it accounts for 48.9 million cases annually, resulting in more than 11 million deaths.\(^{39}\) In the UK, around 250,000 cases and 44,000 deaths of sepsis are reported every year.\(^{40,41}\) In the United States, 1.7 million cases are diagnosed and 270,000 of these cases die from sepsis.\(^{42}\) Very little is known about the estimates of the incidence and outcome of sepsis from developing countries, especially Saudi Arabia. However, all the available data confirm that sepsis is a serious cause of morbidity and mortality all over the world. Approximately two-thirds of septic patients are treated in intensive care units (ICU) with an estimated cost of £15.6 billion in the UK\(^{41}\) and $24 billion in the United States.\(^{39}\) The current management guidelines applied for sepsis, including antibiotics and fluid replacement, are crucial and lead to significant improvement in clinical outcomes and reduction in mortality.\(^{43}\) However, some patients may still die and this maybe owing to the difficulty in assigning a patient’s disease course to the relative over- or under inflammation that may occur,\(^{44}\) or microbial adaptation within the host in the form of acquiring resistance genes to the applied antibiotics (bacterial sepsis).\(^{45}\) Development of new adjunctive therapy to improve the disease might be helpful in those cases when standard care is not sufficient.

Although there is no consensus in the literature about 25(OH)D plasma concentrations used to define VD deficiency, it is a highly prevalent condition worldwide.\(^{46–48}\) The minimum agreement to date is that maintaining a plasma level of 25(OH)D above 30 nmol/l shields against VD deficiency-associated bone disorders; a lower 25(OH)D level could be used to define VD deficiency and should be prevented and treated.\(^{46}\) Based on the 25(OH)D cutoff of <30 nmol/l, VD deficiency is very common worldwide\(^{49}\) with a reported prevalence of 13% in Europe, 5.9% in the United States, 7.4% in Canada, and more than 20% in many developing countries.\(^{50}\) The reported worldwide prevalence is much higher when VD deficiency is defined as <50 nmol/l. It is estimated as 40% in Europe, 24% in the United States, 37% in Canada,\(^{50}\) 34–22% in Africa,\(^{48}\) and 60% in Saudi Arabia.\(^{51}\)

Low VD plasma levels have been observed in 79% to 98% of critical care unit patients, involving septic cases.\(^{52–54}\) The risk of sepsis and its consequential outcomes such as death rate, length of hospital stay, and organ failure are positively correlated with VD deficiency.\(^{52,55}\) Trongtrakul and Feemuchang found that three-quarters of patients who are diagnosed with severe sepsis had a low plasma level of VD and a higher death rate, especially in cases where VD plasma levels were severely deficient (25(OH)D <30 nmol/l).\(^{29}\) In the developed world, the number of new cases of sepsis as well as its related deaths are elevated during winter when low plasma levels of VD are detected,\(^{17}\) albeit that various seasonal factors are also implicated.\(^{56}\) Thus, restoring the VD to optimal plasma levels could have a valuable impact on sepsis development and outcomes. To date, the suggested recommended plasma concentrations of 25(OH)D that are considered sufficient or optimal vary in different settings. Concentrations of >50 nmol/l are sufficient for bone health maintenance, although concentrations of 60–75 nmol/l are suggested for optimal beneficial effects on bone health. However, several studies note that higher levels of above 75 nmol/l are needed for optimal function of the immune system.\(^{57,58}\) Thus, it is very important to conduct further studies to determine optimal plasma levels for VD to exert its extra skeletal functions. In the developing world, data regarding the link between VD deficiency and sepsis is very limited. However, with the high reported prevalence of VD deficiency, increasing hospital admissions of septic patients with VD deficiency are to be expected. Future studies to estimate the VD levels among patients with sepsis and to correlate plasma level with various inflammatory mediators and disease outcomes are required.

**Vitamin D Mechanisms to Interfere with Sepsis Development**

In (bacterial) sepsis, damage and stress signals resulting from invading microorganisms and associated inflammatory responses stimulate intracellular VD activity locally to ensure efficient clearance of the microorganisms and mediate anti-inflammatory and tolerogenic effects.\(^{59}\) Stimulation of the TLR 2/1 pathway by binding to various pathogen-associated molecular patterns (PAMPs) results in induction of VDR and 1-α-hydroxylase (CYP27B1) genes.
Inflammatory mediators such as IFNγ, IL-15, and IL-17A contribute to 1α-hydroxylase (CYP27B1) gene activation.60,61 The majority of immune cells, such as lymphocytes, macrophages, neutrophils, and dendritic cells, as well as vascular endothelial cells have 25-hydroxyvitamin D-1α-hydroxylase (1α-OHase), which acts locally to convert 25-hydroxy-vitamin D (circulating form of VD), to its active compound (1,25(OH)2D).62 Unlike the conventional renal activation of VD, this conversion is regulated by 25-hydroxy-vitamin D levels; thus, low concentration of 25-hydroxy-vitamin D interferes with its extra-skeletal actions.63,64 After activation, VD is translocated intracellularly, in association with a protein called VD binding protein and attach to its nuclear receptors (VDR) forming a complex. Subsequently, this complex attaches to the VD response element on DNA to regulate target gene transcription.60,65,66

VD receptor is expressed by most immune system cells. Thus, signaling through the VD receptor intensifies the local innate immune response by augmenting the release of antimicrobial peptides (AMPs) such as cathelicidin and LL-37, the active form of cathelicidin.67 Such AMPs induce a broad spectrum of antimicrobial activity mediated by cytokine release, including chemotaxis, phagocytosis, and programmed cell death.68 VD reduces antigen presentation processes by decreasing the expression level of major histocompatibility complex (MHC) class II and co-stimulatory molecules, CD40, CD80, CD86, on antigen presenting cells (APCs) such as dendritic cells (DC), resulting in a more tolerogenic, immature state.69 It also has various effects on the activation status of cells mediating adaptive immunity.70–72 VD suppresses T lymphocytes (Th1) and their release of IL-2 and interferon gamma (IFNγ).73,74 Furthermore, the intracellular downstream signaling initiated by the VD-VDR complex in the vascular endothelium reduces cell activity and inflammatory response.75 Moreover, VD has an anti-inflammatory effect. Four hours pre-incubation of immune cells extracted from blood of normal individuals with 100 nM 1,25(OH)2D3, reduced the production of several pro-inflammatory mediators (such as IL-1β, TNF-α, and IFN-γ and IL-8), a 53-fold in response to their 24 h-treatment with bacterial stimulus [heat-killed pneumococcal serotype 19F (HK19F)].76 Another study found that activating blood immune cells isolated from VD deficient samples with TLR stimuli released a wide range of proinflammatory mediators, which were significantly decreased after VD treatment.77

VD exerts its anti-inflammatory actions by suppressing the gene expression of Toll-like receptor-2 and Toll-like receptor-4, reducing p38 and p42/44 phosphorylation and its downstream signaling, as well as decreasing the release of reactive oxygen species.78 In addition, VD acts as a transcription factor to regulate the gene expression of several biological processes controlling immune response, such as cellular proliferation, differentiation, apoptosis, and angiogenesis.79 Furthermore, VD deficiency results in disturbance of the gut microbiome,80 which has an emerging role in sepsis pathogenesis as it increases the susceptibility to sepsis and enhances subsequent multiorgan failure.81,82 VD and VDR both play a significant role in maintaining the normal balance of gut microbiota,83 which in turn boosts immunity against enteric and systemic pathogens.84 Currently, multiple sepsis intervention approaches aimed at restoration of a balanced gut microbiota are under investigation.82 Thus, VD could be used as an adjuvant to enhance their therapeutic effects.

**Effect of Vitamin D on Platelet Leukocyte Aggregation**

Platelet leukocyte aggregates are liberally generated during sepsis and correlate significantly with diseases severity.85 The engagement of white blood cells (WBCs) with activated platelets producing cellular aggregates (moving freely in blood or attached to endothelial cells) contributed substantially to provoking and exacerbating organ dysfunction in septic cases.86 Thus, targeting this pathology at a specific time point in disease duration may limit the severity of sepsis outcomes such as vascular occlusion, decreased blood supply, and organ failure. PLA formation and their attachment to the endothelial lining of the vascular system may be triggered and propagated by a broad spectrum of activated mediators, such as adhesion molecules, proinflammatory cytokines, chemokines, complements, and procoagulant factors, as illustrated in Figure 1. This leads to sustained endothelial dysfunction, increased platelet and leukocyte reactivity, and activation of coagulation.87

As VDR is expressed genetically by most of the cells implicated in PLA formation, such as lymphocytes, neutrophils, macrophages, and vascular endothelial cells,88 VD may affect the formation of these aggregates. Recently, it was shown that healthy individuals with deficient VD have a high level of circulating PLAs and leukocyte endothelial adhesion.89 However, there is no
reported clinical data of the effect of VD administration on the extent of PLAs. It has also been found that VD reduces the expression of adhesion molecules required for platelet activation and decreases homotypic platelet aggregation and platelet–platelet complexes. Therefore, it becomes crucial to consider the impact of VD and VDR in the formation of PLAs.

The first immune defense after infection is initiated by recognizing pathogen associated molecular patterns (PAMPs) and the released damage associated molecular pattern from tissue (DAMPs) by recognition receptors (RRs) such as toll-like receptors (TLRs). RRs are expressed by leukocytes and to a certain degree by endothelial cells and platelets, and result in the stimulation of intracellular signaling pathways and release of inflammatory cytokines such as IL-1, TNFα, IL-6, IL-8, and IL-12. VD downregulates the gene expression of TLRs, thus reducing inflammatory responses. Moreover, VD decreases many proinflammatory mediators such as IL-6, IL-8, and TNFα, which themselves induce the stimulation of leukocytes, platelets, and endothelial cells and lead to the formation of PLAs.

The plasma level of VD is inversely correlated with mean platelet volume (MPV), a marker for platelet activity, noting that platelets with larger size are more active. Activated platelets secrete CD40 ligand
(CD40-L) into the blood, which interacts with CD40 receptors present on platelets to enhance its activation, and on leukocytes to augment its activation and generation of reactive oxygen species, ROS. Furthermore, it may bind to CD40 receptors expressed on vascular endothelial cells amplifying its activation and its expression of several adhesion molecules, such as ICAM and VCAM, on their surface and its production of the chemokine CCL2, thus mediating leukocyte recruitment.

Recently, it has been found that the administration of VD reduces gene expression of the CD40 ligand by blood cells, and serum levels of ICAM and VCAM that are secreted by stimulated endothelium. Angiopoietin 2 (Ang-2) is produced immediately from endothelial Weibel–Palade bodies upon their activation. Ang-2 interacts with Tie 2 receptors in a competitive manner to inhibit the protective effect of Ang-1. Strengthen the activation of endothelium, and exaggerate the inflammation. Additionally, it interacts synergistically with other inflammatory cytokines to boost their actions; for example, sensitizing the vascular endothelium to stimulation with TNFα. It also induces the direct activation of polymorphonuclear cells towards the proinflammatory state. VD administration causes a considerable reduction in the serum level of angiopoietin-2. The interaction of triggering receptors expressed on myeloid cells (TREM-1) on platelets with their ligand on leukocytes is another mediator of PLAs. VD has been reported to inhibit the induced expression of TREM-1 in vitro.

Tissue factor is expressed by activated endothelium, platelets, leukocytes, and their released microparticles, bearing procoagulant and proinflammatory properties, upon activation. It stimulates the extrinsic pathway of coagulation and generates thrombin and fibrinogen. These are important for the following reasons: Thrombin enhances adhesion molecule expression on the surface of the vascular endothelium such as E and P selection and production of von Willebrand factor (VWF) as well as several soluble secretory products, including platelet activating factor, IL-8, and angiopoietin 2. Fibrinogen stabilizes platelet leukocyte endothelial cell interaction by binding to Mac-1 on leukocytic cells and GPIIb/IIIa (αIIbβ3) on platelets and it also binds to CD11b/CD18 on leukocytic cells and intracellular adhesion molecule −1 (ICAM-1) on endothelial cells.

VD downregulates the expression of tissue factor in vitro. Treatment of an activated (inflamed) endothelial cell line with VD suppresses gene expression for tissue factors and adhesion molecules. Furthermore, treatment with VD in patients with chronic kidney disease who have endothelial dysfunction with high serum levels of circulating microparticles leads to a significant reduction in the level of microparticles; it has also been found to inhibit microparticle release from a human endothelial cell line after their exposure to oxidative stress. Moreover, supplementing high doses of VD decreases thrombin production in severely VD deficient patients.

### Potential Confounders of Vitamin D Supplementation in Sepsis

The current in vitro and observational data, discussed in this review, argue for the usefulness of VD supplementation in sepsis. Several RCTs, as summarized in Table 1, have been conducted to evaluate the effect of VD supplementation on the clinical outcome of critical illnesses including sepsis, but their results are contradictory, and the correlation has not been confirmed in all studies.

The results obtained to date warrant further in-depth studies to determine the underlying mechanisms or factors that interfere with yielding the expected protective influences of VD on the progression and outcomes from sepsis. Herein, this part of the review addresses several factors which may confound the effectiveness of VD supplementation.

First, variability in the applied intervention methods regarding the dose, form, route, and duration of VD supplementation as well as heterogeneity of the population and sample size seen across the published RCTs could largely contribute to the reported mixed results. Second, there is a lack of clarity and consistency regarding definitions of VD deficiency and sufficiency in the literature, which produce a significant variation in the criteria of VD deficiency among RCTs. Thus, non-VD deficient cases could be involved in RCTs and have influenced the reported results.

Third, there is an inadequacy of prospective studies to determine the optimal VD dose for extra skeletal tissue functions. Moreover, the exact plasma concentration of VD to replace an insufficiency is controversial in patients with sepsis and its measurement must be interpreted cautiously. VD is physiologically distributed as free (0.3%), or bound to either VD binding protein (DBP; 85%) or albumin (15%). Both DBP level and polymorphic variants affect the bioavailability of VD (free and bound to albumin) and this could affect the response to supplementation.
In some patients, DBP is low due to protein catabolism or leakage to the extracellular matrix owing to increased vascular permeability. In the laboratory, VD sufficiency is commonly determined by measuring the plasma level of total vitamin 25(OH)D. Thus, the bioavailability of free VD (active form) is increased and it can diffuse into most body cells. Additionally, the higher rate of polymorphism in the gene encoding VDBP (GC gene) results in DBP isoforms with different binding affinities to VD, which affect the bioavailability of VD. Additional VD supplementation therefore requires attention because it may lead to higher risk of hypercalcemia. Approximately 1% of mild hypercalcemia not requiring clinical intervention was reported among septic patients following VD administration. At the molecular level, any increase in extracellular (serum) calcium ions affects the inflammatory response. Extracellular Ca\(^{2+}\) act as a danger signal (DAMPs), and amplify inflammation. Moreover, septic patients may be classified as VD deficient based on their plasma level of total vitamin 25(OH)D, even if the bioactive free form of VD is within normal values. Consequently, supplementation of VD may not produce the expected positive effects.

VD levels are important in the maintenance of circulating immunoglobulins and complement. A large study has documented, for low levels of VD, a positive association with IgG2 and C4 and a negative association for IgA (complement binding), IgG1, and C3. These changes are of particular relevance in cases of systemic inflammatory reactions, which draw initially on intact mucosal barriers and a humoral component of the immune response. Depletion of complement components following overactivation and deposition in tissue (consumption in the blood phase) may be a determinant of overall outcome. Sepsis associated multiple-organ dysfunction, in which complement activation products and complement dysregulation have an undisputed pathogenic role, may well be influenced by specifically targeting pathways or components thereof. However, the timing of such an intervention for it to be effective and efficient may be difficult to judge. Septic patients suffer initially from an uncontrolled excessive inflammatory response followed by immune suppression.

Therefore, proper timing of VD supplementation could significantly influence its supplementation outcomes. Modes of action may include pleiotropic effects on lipid metabolism, which are altered in the context of sepsis. VD deficiency is correlated with high levels of cholesterol, triglycerides, and low-density lipoproteins (LDL). VD supplementation leads to a reduction in lipid parameters, total cholesterol, very-low-density lipoproteins (VLDL), LDL, and triglycerides, which could be falsely interpreted as sepsis, because low lipid profiles are positively associated with poor sepsis outcome.

Thus, it appears that timing and dose of VD supplementation in sepsis influence its effectiveness and this could be a contributing factor to the controversy in the reported results of interventional studies. Detailed understanding of the molecular basis of VD metabolism and the regulation of its bioavailability during the course of sepsis is required to determine its effectiveness.

Conclusion
VD deficiency is prevalent in cases with sepsis, thus, its deficiency may affect disease pathogenesis and aggravate the condition. VD has immunomodulatory effects. Restoration of VD plasma levels may limit disease progression through decreasing the abundance of DAMPs and PAMPs, inflammatory mediators, extent of PLAs formation and their adhesion to endothelia, and balancing the gut microbiota to fight systemic and enteric pathogens. However, data available from the literature regarding the influence of VD supplementation are conflicting in patients with sepsis and disagree with current evidence from in vitro and observational studies. Several factors may underestimate the expected positive effects. Further studies are warranted to elucidate the molecular interactions of VD with different players involved in the pathogenesis of sepsis (immune homeostasis). Thus, proper timing of VD supplementation, dose, form, and its sufficient plasma levels to be effective, as well as identifying patients who may benefit the most from supplementation with VD, need to be accurately determined in future clinical trials. Targeting the population with severe VD deficiency below 30 nmol/l is highly suggested for future trials.

Acknowledgments
The author would like to thank Prof. Suhad Bahijri, and Dr. Cordula Stover for her support in reviewing this manuscript.

Disclosure
The author declares no conflicts of interest.
References

1. Tintut Y, Demer LL. Potential impact of the steroid hormone, vitamin D, on the vasculature vitamin D- hormones and cardiovascular disease. Am J Heart. 2021;239:147–153. doi:10.1016/j.ajh.2021.05.012.

2. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: molecular mechanism of action, and pleiotropic effects. Physiol Rev. 2016;96:365–408. doi:10.1152/physrev.00014.2015.

3. Tripkovic L, Lambert H, Hart K, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr. 2012;95:1357–1364. doi:10.3945/ajcn.111.031070.

4. Siddiqui M, Manansala JS, Aubrahmanya HA, et al. Immune modulatory effects of vitamin D on viral infections. Nutrients. 2020;12:2879. doi:10.3390/nu12092879.

5. Demer LL, Hsu JJ, Tintut Y. Steroid hormone vitamin D: implications for cardiovascular disease. Circ Res. 2018;122:1576–1585. doi:10.1161/CIRCRESAHA.118.311585.

6. Dattola A, Silvestri M, Bennardo L, et al. Role of vitamins in skin health: a systematic review. Cure Nutr Rep. 2020;1–10.

7. Aranow C. Vitamin D and the immune system. Annu Rev Physiol. 2019;81:1–25.

8. Grant AH. The effect of Rachitic diets on experimental tuberculosis: III. resistance to tuberculosis decreased by adding codliver oil. Am Rev Tuberc. 1930;31:102–114.

9. Banyai AL. Topical application of codliver oil in tuberculosis: what it is currently (not) understood. Am Rev Tuberc. 1927;2(3475):258. doi:10.1136/bmj.2.3475.258.

10. Coulter JS, Carter HA. The treatment of pulmonary tuberculosis by ultraviolet radiation. J Am Med Assoc. 1935;105:171–174. doi:10.1001/jama.1935.02760290005003.

11. Gerstenberger HJ, Burhans CW. Treatment of extensive pulmonary tuberculosis with ultraviolet rays. Am J Dis Child. 1927;33:54–73.

12. Finsen NR. Phototherapy: 1. The Chemical Rays of Light and Smallopox, 2. Light as a Stimulant, 3. The Treatment of Lupus Vologarhs Concentrated Chemical Rays. Arnold; 1901.

13. Lang PO, Aspinall R. Vitamin D status and the host resistance to infections: what it is currently (not) understood. Clin Ther. 2017;39:930–945. doi:10.1016/j.clinthera.2017.04.004.

14. Semon HC. The treatment of lupus erythematosus by kryosgalon. Br Med J. 1927;2(3475):258. doi:10.1136/bmj.2.3475.258.

15. Khayat A, Amirhakimi G. The rachitocic lung: pulmonary findings in 30 infants and children with malnutritional rickets. Am J Dis Child. 1927;33:54–73.

16. Finsen NR. Phototherapy: 1. The Chemical Rays of Light and Smallopox, 2. Light as a Stimulant, 3. The Treatment of Lupus Vologarhs Concentrated Chemical Rays. Arnold; 1901.

17. Upala S, Sanguankeo A, Permpalung N. Significant association between vitamin D deficiency and sepsis: a systematic review and meta-analysis. BMC Infect Dis. 2020;20:1–10.

18. Zhou W, Mao S, Wu L, Yu J. Association between vitamin D status and sepsis. Clin Lab. 2018;64:451–460. doi:10.7754/ClinLab.2017.170919.

19. McNally JD, Leis K, Matheson LA, Karuannya C, Sankaran K, Rosenberg AM. Vitamin D deficiency in young children with severe acute lower respiratory infection. Pediatr Pulmonol. 2009;44:981–988. doi:10.1002/ppul.21089.

20. Kempter JA, Han JE, Tangpricha V, Ziegler TR, Martin GS. Vitamin D and sepsis: an emerging relationship. Dermato-Endocrinology. 2012;4:101–108. doi:10.4161/derm.19859.
56. Fares A. Factors influencing the seasonal patterns of infectious diseases. J Thorac Dis. 2017;9:943. doi:10.21037/jtd.2017.03.125
55. de Haan K, Groeneveld AJ, de Geus HR, Egal M, Struijs A. Vitamin D deficiency in critically ill patients and its influence on outcome: a systematic review and meta-analysis. Lancet. 2020;395:200–211. doi:10.1016/S0140-6736(19)32989-7
54. Daniels R. Sepsis: the silent killer we should be stopping. Br J Nurs. 2020;29:519–521. doi:10.12968/bjon.2020.29.7.519
53. Daniels R. Sepsis: the silent killer we should be stopping. Int J First Aid Educ. 2018;1:23. doi:10.21038/ijfse.2018.0005
52. Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009–2014. JAMA. 2017;318:1241–1249. doi:10.1001/jama.2017.13836
51. Plevin R, Callcut R. Update in sepsis guidelines: what is really new? Trauma Surg Acute Care Open. 2017;2:e000088. doi:10.1136/tsaco-2017-000088
50. Roth DE, Abrams SA, Aloia J, et al. Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low-and-middle-income countries. Ann N Y Acad Sci. 2018;1430:44. doi:10.1111/nyas.13968
49. Giustina A, Adler R, Binkley N, et al. Consensus statement from 2 nd International Conference on Controversies in Vitamin D. Rev Endocr Metab Disord. 2020;21:89.
48. Mogire RM, Mutua A, Kimita W, et al. Prevalence of vitamin D deficiency in Africa: a systematic review and meta-analysis. J Glob Health. 2020;8:e134–e142. doi:10.1016/S2214-109X(19)30457-7
47. Pilz S, Zittermann A, Trummer C, et al. Vitamin D testing and treatment: a narrative review of current evidence. Endocrinol Connect. 2019;8:R27–R43.
46. Kempker JA, Tangpricha V, Ziegler TR, Martin GS. Vitamin D and critical illness: what endocrinology can learn from intensivists. Int J First Aid Educ. 2018;7:R304–R315. doi:10.1530/EC-18-0184
45. Al-Alyani H, Al-Turki HA, Al-Essa ON, Alani FM, Sadat-Ali M. Vitamin D deficiency in Saudi Arabians: a reality or simply hype: a meta-analysis (2008–2015). Crit Care. 2015;19:251.
44. Azim A, Ahmed A, Yadav S, et al. Prevalence of vitamin D deficiency in critically ill patients and its influence on outcome: experience from a tertiary care centre in North India (an observational study). J Intensive Care. 2013;1:1–5. doi:10.1186/2052-0492-1-14
43. Amrein K, Scherkl M, Hoffmann M, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr. 2020;74:1498–1513. doi:10.1038/s41366-020-0558-y
42. Al-Alhaj H, Al-Turki HA, Al-Essa ON, Alani FM, Sadat-Ali M. Vitamin D deficiency in Saudi Arabsians: a reality or simply hype: a meta-analysis (2008–2015). J Family Community Med. 2018;25:1.
41. Alharbi A, Alahgholi-Hajibehzad M. Vitamin D3 inhibits the proliferation of T helper cells, downregulate CD4+ T cell cytokines and upregulate inhibitory markers. Hum Immunol. 2018;79:439–445. doi:10.1016/j.humimm.2018.03.001
40. Amrein K, Papinutti A, Mathew E, Vila G, Bergman P, Björkhem-Bergman L. Are vitamin D3 tablets and oil drops equally effective in raising S-25-hydroxyvitamin D concentrations? A post-hoc analysis of an observational study on immunodeficient patients. Nutrients. 2020;12:1230. doi:10.3390/nu12051230
39. Chirumbolo S, Bjorklund G, Sooarina A, Vella A. The role of vitamin D in the immune system as a pro-survival molecule. Clin Ther. 2017;39:894–916. doi:10.1016/j.clinthera.2017.03.021
38. Alharbi A, Alahgholi-Hajibehzad M. Vitamin D signaling in endothelial cell leads to an enhanced leukocyte-endothelium interplay: implications for atherosclerosis development. PLoS One. 2015;10:e0136863. doi:10.1371/journal.pone.0136863
37. Vile G, Parpura V, De La Torre J. Impairment in Toll-like receptor-2 and cytokine profile: a pilot study. J Transl Med. 2013;11:1–7. doi:10.1186/1479-5876-11-176
78. Calton EK, Keane KN, Newsholme P, Soares MJ. The impact of vitamin D levels on inflammatory status: a systematic review of immune cell studies. *PLoS One*. 2015;10:e0141770. doi:10.1371/journal.pone.0141770

79. Umar M, Sastry KS, Chouchane AI. Role of vitamin D beyond the skeletal function: a review of the molecular and clinical studies. *Int J Mol Sci*. 2019;18:19168. doi:10.3390/ijms1916168

80. Haak BW, Wiersinga WJ. The role of the gut microbiota in sepsis. *Lancet Gastroenterol Hepatol*. 2017;2:135–143. doi:10.1016/S2468-125X(16)30119-4

81. Haak BW, Prescott HC, Wiersinga WJ. Therapeutic potential of the gut microbiota in the prevention and treatment of sepsis. *Front Immunol*. 2018;9:2042. doi:10.3389/fimmu.2018.02042

82. Miller WD, Keskey R, Alverdy JC. Sepsis and the microbiome: a vicious cycle. *J Infect Dis*. 2021;223:S264–S269.

83. Akimbekov NS, Digel I, Sherelkhan DK, Lutfor AB, Razzaque MS. Emerging role of vitamin D and the host-gut microbiome: a brief overview. *Acta Histochem Cytochem*. 2020;53:33–42. doi:10.1267/ahc.20011

84. Bassetti M, Bandera A, Gori A. Therapeutic potential of the gut microbiota in the management of sepsis. *Crit Care*. 2020;24:1–7. doi:10.1186/s13054-020-2780-3

85. Sadeghi K, Wessner B, Laggner U, et al. Vitamin D3 downregulates monocyte and heterotypic aggregate formation in sepsis. *Front Immunol*. 2018;9:2042. doi:10.3389/fimmu.2018.02042

86. Wang X, Qin W, Sun B. New strategy for sepsis: targeting a key role of mean platelet volume and vitamin D deficiency in fibromyalgia. *J Nippon Med Sch*. 2020;87:196–198. doi:10.1111/jnms.1314.x

87. Mohammad S, Mishra A, Ashraf MZ. Vitamin D concentrations in patients with stable coronary artery disease. *Cytokine*. 2020;119:60–63. doi:10.1016/j.cyto.2020.02.010

88. Sriskandan S, Altmann D. The immunology of sepsis. *J Pathol*. 2008;214:211–223. doi:10.1002/path.2274

89. Alharbi

90. Akimbekov NS, Digel I, Sherelkhan DK, Lutfor AB, Razzaque MS. Emerging role of vitamin D and the host-gut microbiome: a brief overview. *Acta Histochem Cytochem*. 2020;53:33–42. doi:10.1267/ahc.20011

91. Sultan M, Twito O, Tøhami T, Ramati E, Neumark E, Rashid G. Relationship between serum 25-hydroxyvitamin D concentrations in patients with stable coronary artery disease. *Heart Vessels*. 2018;33:1275–1281. doi:10.1007/s00380-018-1182-9

92. Sriskandan S, Altmann D. The immunology of sepsis. *J Pathol*. 2008;214:211–223. doi:10.1002/path.2274

93. Matsuda A, Jacob A, Wu R, et al. Novel therapeutic targets for sepsis: regulation of exaggerated inflammatory responses. *J Nippon Med Sch*. 2012;79:4–18. doi:10.1272/jnms.79.4

94. Cognasse F, Hanzech H, Chavarin P, Acquart S, Genin C, Garraud O. Evidence of Toll-like receptor molecules on human platelets. *Immunol Cell Biol*. 2005;83:196–198. doi:10.1111/j.1440-1711.2005.01314.x

95. Sadeghi K, Wessner B, Laggner U, et al. Vitamin D3 downregulates monocyte TLR expression and triggers hypersensitivity to pathogen-associated molecular patterns. *Eur J Immunol*. 2006;36:361–370. doi:10.1002/eji.200425995

96. Adegoke SA, Smith OS, Adekile AD, Figueredo MS. Relationship between serum 25-hydroxyvitamin D and inflammatory cytokines in paediatric sickle cell disease. *Cytokine*. 2017;96:87–93. doi:10.1016/j.cyt.2017.03.010

97. Korzeneck-Szacheta I, Hudzik B, Nowak J, et al. Mean platelet volume is associated with serum 25-hydroxyvitamin D concentrations in patients with stable coronary artery disease. *Heart Vessels*. 2018;33:1275–1281. doi:10.1007/s00380-018-1182-9
For personal use only.

115. Creager M, Loscalzo J, Beckman JA. *Vascular Medicine E-Book: A Companion to Braunwald’s Heart Disease*. Elsevier Health Sciences; 2012.

116. Sugama Y, Tiruppathi C, Andersen T, Fenton J, Malik A. Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1: a mechanism for stabilizing neutrophil adhesion. *J Cell Biol*. 1992;119:935–944. doi:10.1083/jcb.119.4.935

117. Meiring M, Allers W, Le Roux E. Tissue factor: a potent stimulator of Von Willebrand factor synthesis by human umbilical vein endothelial cells. *Int J Med Sci*. 2016;13:759. doi:10.7150/ijms.15688

118. Ueno A, Murakami K, Yamanouchi K, Watanabe M, Kondo T. Thrombin stimulates production of interleukin-8 in human umbilical vein endothelial cells. *Immunolology*. 1996;88:76–81. doi:10.1046/j.1365-2567.1996.d01-635.x

119. Hellter R, Bussolino F, Ghigo D, et al. Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells. *Biochem Pharmacol*. 1992;44:223–229. doi:10.1016/0006-2952(92)90004-3

120. Huang Y-Q, Li J-J, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. *Blood*. 2002;99:1646–1650.

121. Rossaint J, Zarbock A. Platelets in leucocyte recruitment and function. *J Cell Biol*. 1992;119:935–944. doi:10.1083/jcb.119.4.935

122. Cimmino G, Morello A, Conte S, et al. Vitamin D inhibits tissue factor and CAMs expression in oxidized low-density lipoproteins-treated umbilical vein endothelial cells. *J Immunol*. 2002;169:5177–5185. doi:10.4049/jimmunol.169.10.5177

123. Lundwall K, Mörtberg J, Mobarrez F, Jacobson SH, Jörneskog G, Spak J. Changes in microparticle profiles by vitamin D receptor activation in chronic kidney disease—a randomized trial. *BMJ Nephrol*. 2019;201:1–10. doi:10.1136/bmjnph.2019.00122

124. Jia X, Xu J, Gu Y, Li W, Wang Y. Vitamin D suppresses oxidative stress-induced microparticle release by human umbilical vein endothelial cells. *Biol Reprod*. 2017;96:199–210. doi:10.1093/bioreprod/biul42604

125. Blondon M, Biver E, Braillard O, Righini M, Fontana P, Casini A. Thrombin generation and fibrin clot structure after vitamin D supplementation. *Endocur Connect*. 2019;8:1447–1454. doi:10.1530/EC-19-0429

126. Guessous I. Role of vitamin D deficiency in extraskelatal complications: predictor of health outcome or marker of health status? *BioMed Res Int*. 2015;2015:1–13. doi:10.1155/2015/563403

127. Lips P, Cashman KD, Lamberg-Allardt C, et al. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. *Eur J Endocrinol*. 2019;180:P23–P54.

128. Bouillon R, Rosen CJ, Mulder JE. Vitamin D and extraskelatal health. *UpToDate*. 2015;7.

129. Takeuti FA, Souza-Fonseca-Guimarães F, Guimarães PS. Applications of vitamin D in sepsis prevention. *Discov Med*. 2018;25:291–297.

130. Reijven P, Soeters P. Vitamin D: a magic bullet or a myth? *Clin Nutr*. 2020;39(9):2663–2674. doi:10.1016/j.clnu.2019.12.028

131. Bikle DD, Schwartz J. Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. *Front Endocrinol (Lausanne)*. 2019;10. doi:10.3389/fendo.2019.00317

132. Bikle D. Vitamin D: production, metabolism, and mechanisms of action. In: Feingold KR, Anawalt B, Boyce A, et al., editors. *Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278935/

133. Xie Z, Wang X, Bikle DD. Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. *Front Endocrinol (Lausanne)*. 2020;11:40. doi:10.3389/fendo.2020.00040

134. Cho M-C, Kim JH, Jung MH, et al. Analysis of vitamin D-binding protein (VDBP) gene polymorphisms in Korean women with and without endometriosis. *Clin Exp Reprod Med*. 2019;46(3):132. doi:10.5653/ermm.2019.00122

135. Mehramriz M, Khayyatzadeh SS, Esmaily H, et al. Associations of vitamin D binding protein variants with the vitamin D-induced increase in serum 25-hydroxyvitamin D. *Clin Nutr*. 2019;29:59–64. doi:10.1016/j.clnesp.2018.12.005

136. Rossol M, Pierer M, Raulien N, et al. Extracellular Ca 2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. *Nat Commun*. 2012;3:1–9. doi:10.1038/ncomms2339

137. Sakem B, Nock C, Stanga Z, et al. Serum concentrations of 25-hydroxyvitamin D and immunoglobulins in an older Swiss cohort: results of the Senior Labor Study. *BMC Med*. 2013;11:176. doi:10.1186/1741-7015-11-176

138. Stover CM, McDonald J, Byrne S, Lambert DG, Thompson JP. Properdin levels in human sepsis. *Front Immunol*. 2015;6:24. doi:10.3389/fimmu.2015.00024

139. Ospina-Caicedo AI, Cardona-Rincón AD, Bello-Gualtero JM, et al. Lower levels of vitamin D associated with disease activity in Colombian patients with systemic lupus erythematosus. *Curr Rheumatol Rev*. 2019;15:146–153. doi:10.2174/157393711466618015161547

140. Karasu E, Nilsson B, Köhl J, Lambris JD, Huber-Lang M. Targeting complement pathways in polytrauma-and sepsis-induced multiple-organ dysfunction. *Front Immunol*. 2019;10:543. doi:10.3389/fimmu.2019.00543

141. Nedeva C, Menassa J, Pathalakath H. Sepsis: inflammation is a necessary evil. *Front Cell Dev Biol*. 2019;7:108. doi:10.3389/fcell.2019.00108

142. Sharma NK, Ferreira BL, Tashima AK, et al. Lipid metabolism impairment in patients with sepsis secondary to hospital acquired pneumonia, a proteomic analysis. *Clin Proteomics*. 2019;16:29. doi:10.1155/s12282-019-1445-4

143. Bashir HA. Effect of vitamin D deficiency on lipid profile. *Am J Lab Med*. 2019;16:29. doi:10.1186/s12014-019-9252-2

144. Bashir NA, Bashir AAM, Bashir HA. Effect of vitamin D deficiency on lipid profile. *Am J Lab Med*. 2019;4:11–18. doi:10.11648/j.ajlm.20190401.12

145. Dibata DT. Effect of vitamin D supplementation on serum lipid profiles: a systematic review and meta-analysis. *Nutr Rev*. 2019;77:890–902. doi:10.1093/nutrit/nuz037

146. Lee SH, Park MS, Park BH, et al. Prognostic implications of serum lipid metabolism over time during sepsis. *Biomed Res Int*. 2015;2015:1–8. doi:10.1155/2015/789298

147. Schwartz V, Scharnagl H, Trummer C, et al. Vitamin D supplementation and lipoprotein metabolism: a randomized controlled trial. *J Clin Lipidol*. 2018;12:588–596. e584. doi:10.1016/j.jacl.2018.03.079
